Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 76Squamous Cell Carcinoma of Head and Neck 43Lung Neoplasms 34Oropharyngeal Neoplasms 22Urinary Bladder Neoplasms 20Head and Neck Neoplasms 18Nasopharyngeal Carcinoma 17Carcinoma 15Biliary Tract Neoplasms 15Small Cell Lung Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Neoplasm Metastasis 13Esophageal Squamous Cell Carcinoma 13Cholangiocarcinoma 13Colorectal Neoplasms 12Uterine Cervical Neoplasms 11Pancreatic Neoplasms 11Neoplasms 11Carcinoma, Squamous Cell 11Ovarian Neoplasms 10Mouth Neoplasms 9Laryngeal Neoplasms 9Gallbladder Neoplasms 8Endometrial Neoplasms 8Carcinoma, Transitional Cell 8Hypopharyngeal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Mesothelioma, Malignant 6

Interventions

lutetium Lu 177 dotatate 12Specimen Handling 6Magnetic Resonance Spectroscopy 6cabozantinib 5Everolimus 5pembrolizumab 4Nivolumab 4olaparib 3lenvatinib 3Cyclophosphamide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3lanreotide 2gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Phantoms, Imaging 2Octreotide 2Lutetium-177 2Ipilimumab 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2tivozanib 1surufatinib 1repotrectinib 1peposertib 1pazopanib 1entrectinib 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Cisplatin × 90 days × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡